MyCural Therapeutics
Developing new cancer therapies for patients with high-risk tumors.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
$1.0m | Early VC | ||
| Total Funding | 000k | ||
| SEK | 2023 | 2024 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 938 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| % profit margin | (7613 %) | (955 %) |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
MyCural Therapeutics is a pioneering biotech startup specializing in cancer research, particularly targeting the MYC oncogene, a critical factor in tumor development. The company operates in the pharmaceutical and biotechnology market, focusing on developing innovative therapies aimed at achieving tumor regression with minimal side effects. MyCural Therapeutics serves a wide range of clients, including pharmaceutical companies, research institutions, and healthcare providers. The business model is centered around research and development, drug discovery, and clinical trials, with revenue generated through partnerships, licensing agreements, and investments from holding companies. The company is actively involved in networking events, business incubators, and pharma conferences, which helps in gaining strategic business support and expanding its network. The core team, led by Dr. Alina Castell, brings extensive expertise in structural biology and tumor biology, further strengthening the company's research capabilities.
Keywords: cancer research, MYC oncogene, tumor regression, biotech startup, drug discovery, clinical trials, pharmaceutical partnerships, structural biology, tumor biology, targeted therapies.